Medline (MDLN) vs Repligen (RGEN)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Medline is the larger company by market cap ($48.03 billion vs $10.32 billion), about 4.7 times the size. On valuation, Medline trades at a lower forward P/E (22.6x vs 61.4x for Repligen). Repligen converts more of its revenue into profit, with a net margin of 6.6% versus 4.1%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | MDLN | RGEN |
|---|---|---|
| Share price | $35.70 | $162.60 |
| Market cap | $48.03B | $10.32B |
| 1-day change | +0.71% | -2.76% |
| YTD return | -15.60% | +2.05% |
| 1-year return | — | +14.59% |
| 5-year return | — | -37.35% |
| P/E ratio (TTM) | 89.25 | 222.74 |
| Forward P/E | 22.64 | 61.37 |
| EPS (TTM) | $0.40 | $0.73 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $28.43B | $738.26M |
| Revenue growth (YoY) | — | +16.36% |
| Net income (latest FY) | $1.16B | $48.89M |
| Gross margin | 26.44% | 52.32% |
| Operating margin | 7.78% | 7.47% |
| Net margin | 4.08% | 6.62% |
| 52-week high | $50.88 | $198.87 |
| 52-week low | $31.49 | $100.99 |
| Distance from 52-week high | -29.83% | -18.24% |
| Analyst consensus | buy | strong_buy |
| Avg. price target upside | +24.65% | +19.90% |
| Average volume | 7.54M | 1.17M |
| Shares outstanding | 877.35M | 63.49M |
| Employees | 45,000 | 2,000 |
| Sector | Health Care | Health Care |
| Industry | Medical/Dental Instruments | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Medline is about 4.7 times larger than Repligen by market value ($48.03B vs $10.32B).
- Repligen trades at a higher earnings multiple (222.7x vs 89.3x trailing P/E).
About Medline
MDLN stock →Medline Inc. manufactures med-surg products serving the hospital, surgery centers, physician offices, post-acute facilities, and nursing home sites of care in the United States and Internationally.
Health Care · Medical/Dental Instruments · 45,000 employees
About Repligen
RGEN stock →Repligen Corporation, a life sciences company, develops and commercializes bioprocessing technologies and systems in North America, Europe, the Asia Pacific, and internationally. The company's products include hollow fiber consumables, KRM chromatography system, resins for new modalities, PATsmart MAVERICK and PATsmart MAVEN for real-time monitoring and control of critical bioprocess parameters, PATsmart REBEL, an at-line cell culture media analyzer; and PATsmart ZipChip, a high-resolution sample separations device, PATsmart SoloVPE slope spectroscopy system, and SoloVPE PLUS System.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 2,000 employees
MDLN vs RGEN FAQ
Which is bigger, Medline or Repligen?
Medline (MDLN) is larger, with a market capitalization of $48.03B compared with $10.32B for Repligen (RGEN).
Which has the lower P/E ratio, MDLN or RGEN?
MDLN has the lower trailing P/E at 89.3, versus 222.7 for RGEN. A lower P/E is not by itself a sign of a better investment; it can reflect slower expected growth or higher risk.
Are Medline and Repligen in the same industry?
Both are in the Health Care sector, but in different industries: Medical/Dental Instruments for Medline and Biotechnology: Biological Products (No Diagnostic Substances) for Repligen.